Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
After a successful Series B fundraising round from Seoul Clinical Laboratories…
TAIPEI, Taiwan, Feb. 25, 2024 /PRNewswire/ -- Taiwan's leading digital health brand, H2U, ushered in the lunar new year with exciting news. Entities such as Korea's largest medical laboratory, Seoul Clinical Laboratories (SCL), Taiwan's biggest food company, Standard Foods, the leading protein and antibody reagent innovator and manufacturer, Leadgene Biomedical, and AWS cloud services representative, GrandTech C.G. Systems, have enthusiastically joined H2U's current round of fundraising (Series…
PR Newswire
25/02/2024
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch…
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticariaLate-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in...
Nasdaq GlobeNewswire
24/02/2024
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk)…
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengthsAlvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced...
Nasdaq GlobeNewswire
24/02/2024
Transactions with shares and linked securities in Genmab A/S made by managerial…
Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to...
Nasdaq GlobeNewswire
23/02/2024
Grant of Restricted Stock Units to Management and Employees and Grant of…
Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally...
Nasdaq GlobeNewswire
23/02/2024
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document…
Filing of the 2023 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial ReportParis, February 23, 2024. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).These documents are available on the company's website:https://www.sanofi...
Nasdaq GlobeNewswire
23/02/2024
Tilray Medical Applauds German Bundestag and Landmark Passage of Medical…
New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG Tilray Medical's Chief Strategy Officer and Head of International Denise Faltischek comments: "The decision to open up the previously limited German medical cannabis market is an important step that will allow patients and physicians to explore effective treatment options tailored to individual needs. Facilitating access to the highest quality cannabis medicines through the new...
Nasdaq GlobeNewswire
23/02/2024
Dental 3D Printing Market Worth $8.1 billion | MarketsandMarkets™
Browse in-depth TOC on "Dental 3D Printing Market" Browse in-depth TOC on "Dental 3D Printing Market" 280 - Tables60 - Figures400 - Pages Dental 3D Printing Market Scope: Based on dental 3D printing market end user, the dental laboratories segment is expected to grow at the highest CAGR during the forecast period. By end user, the dental 3D printing market can be segmented into dental laboratories, dental hospitals & clinics, and dental academic & research...
PR Newswire
23/02/2024
Maxima Estonia CEO – D. Gegelytė
As of February 24, Diana Gegelytė was appointed as the sole member (CEO) of the board of MAXIMA Eesti OÜ, succeeding Kristina Mustonen. D. Gegelytė joined “Maxima LT“ in 2011 as the Head of Labour Safety and Health Unit. Since 2016, she has served as the Head of Operations Area Projects, serving in this position until 2020, when she assumed the role of Director of Trade and Production Department of „Maxima Eesti“. Most recently D. Gegelytė has been serving as the Chief Operating Officer of...
Nasdaq GlobeNewswire
23/02/2024
Curia Appoints Steve Lavezoli as Vice President, Biologics
ALBANY, N.Y., Feb.23, 2024(GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia's biologics division, overseeing its discovery, development and manufacturing services. “This is an exciting time for our biologics team, and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb. “Steve's remarkable breadth...
Nasdaq GlobeNewswire
23/02/2024
Biogen's QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of…
SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe 1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field CAMBRIDGE, Mass., Feb.23, 2024(GLOBE NEWSWIRE) --Biogen Inc.(Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted...
Nasdaq GlobeNewswire
23/02/2024
Polyurethane Foam Market Size to Grow USD 64440 Million by 2030 at a CAGR of…
Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-39A12096/Global_Polyurethane_Foam_Industry_Research_Report_Growth_Trends_and_Competitive_Analysis_2022_2028 Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Auto-39A12096/Global_Polyurethane_Foam_Industry_Research_Report_Growth_Trends_and_Competitive_Analysis_2022_2028 Major Factors Driving the Growth of Polyurethane Foam Market The market for polyurethane foam is...
PR Newswire
23/02/2024
PRADA FALL/WINTER 2024 WOMENSWEAR SHOW
To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9252851-prada-fall-winter-2024-womenswear-show/ To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9252851-prada-fall-winter-2024-womenswear-show/ **FACE** Lynsey Alexander starts by preparing the skin with Prada Skincare, employing Prada Augmented Skin The Essence as the first step. This transformative 2-in-1 toner and micro-peel essence optimizes and renews skin...
PR Newswire
23/02/2024
Pierre Fabre Laboratories, committed to combating rare pediatric diseases via…
In this area more than any other, partnerships are essential for driving research forward and discovering new treatments. In this area more than any other, partnerships are essential for driving research forward and discovering new treatments. Working with the EspeRare Foundation to treat XLHED: Pierre Fabre Laboratories is committed, alongside the EspeRare Foundation, to developing an innovativein uterotherapy for the most common form of ectodermal dysplasia, XLHED, a rare genetic...
PR Newswire
23/02/2024
Vantage Foundation partners with The IREDE Foundation to empower child amputees…
Vantage Foundation visited The IREDE Foundation in February to pledge support for their cause. "We are thrilled to support the IREDE Foundation to make a positive impact on the lives of Nigerian children with limb loss," said Steven Xie, Executive Director, Vantage Foundation. "As a partner of The IREDE Foundation, we will provide holistic support to these champions in Nigeria, and provide the opportunities they deserve to thrive." Vantage Foundation visited The IREDE…
PR Newswire
23/02/2024
Lancet Digital Health Publishes Study Confirming MAGENTIQ-COLO™ AI-aided…
The study, titled "A novel computer-aided polyp detection system in screening and surveillance colonoscopy: an international multicentre, randomised, tandem trial," was performed over a period of 14 months across 10 leading medical centers, 31 endoscopists, and 952 screened and enrolled patients. The study, titled "A novel computer-aided polyp detection system in screening and surveillance colonoscopy: an international multicentre, randomised, tandem trial," was performed…
PR Newswire
23/02/2024
United Imaging Showcases AI-Driven Innovations and Expands European Presence at…
Lukasz MIZERKA, vice president of United Imaging international business and general manager for Europe, added, "Last March, we held our first brand launch at ECR, officially introducing our passion for change to the European market. During the year, we achieved swift progress, extending our footprint to numerous European countries with our high-end equipment, serving as testament to the resonance of our mission of bringing 'equal healthcare for all'. This year marks both our second ECR and…
PR Newswire
23/02/2024
Aino Health year-end report January-December 2023
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Implemented 100,000 licences. Solid growth according to plan. Improved profitability and cash flow from operations. October - December 2023Net sales were 6 313 (4 661) TSEK Profit/loss after financial items was SEK -3,851 (-4,440) TSEKEarnings per share were SEK 0 (-0.1) January - December 2023 Net sales were 23 918 (19 908) TSEK...
Nasdaq GlobeNewswire
23/02/2024
Mendus to hold Business Update event on March 12
Press Release Stockholm, Sweden, February 23, 2024Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discuss the company's latest pipeline advancements. Mendus has recently presented positive Phase 2 data with vididencel in acute myeloid leukemia (AML), an aggressive blood-borne tumor associated with high relapse rates, at the ASH 2023 conference. Vididencel addresses the need for safe and...
Nasdaq GlobeNewswire
23/02/2024
Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment…
Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024.COPENHAGEN, Denmark, February 23, 2024– Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation Application (MAA) for...
Nasdaq GlobeNewswire
23/02/2024
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of…
Dupixent ®sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation Priority Review granted based on positive results from two Phase 3 trialsIf approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more than a decadeRegulatory submissions are also under review in China and Europe Paris and Tarrytown, N.Y. February 23, 2024.The U.S. Food and Drug Administration (FDA) has...
Nasdaq GlobeNewswire
23/02/2024
LG'S HOME LIFESTYLE SOLUTIONS PRESENT COMFORT AND CONVENIENCE AT KBIS 2024
Bath Solution for an Enhanced Bathroom Experience LG is expanding enhanced customer experience to the bathroom, one of the main living spaces in the home, by presenting a bath solution that provides convenience and comfort. LG's Smart Bath and Shower Purifier offers a refreshing shower experience, delivering clean, purified water through an advanced water filter. The system intelligently monitors water usage and provides timely filter replacement alerts to help facilitate a consistently pure…
PR Newswire
23/02/2024
Galapagos announces full year 2023 results and outlook for 2024
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burn iof €414.8 million, within guidance2023 and year-to-date key updates : Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product...
Nasdaq GlobeNewswire
22/02/2024
United States Pharmaceuticals Market Size to Surpass US$ 1,068.02 Billion by…
The United States Pharmaceuticals Market is driven by two main factors. Firstly, the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is fueling the demand for pharmaceutical products. With the growing aging population and unhealthy lifestyles, the incidence of chronic diseases is on the rise, leading to a higher demand for effective medications. Additionally, the rising awareness and accessibility of healthcare facilities across the country are…
PR Newswire
22/02/2024
Altri Comunicati
